Supporting our observations, Wang et al. [113] showed that CACNA2D4 played a role in mitigating the adverse effects of first-line chemotherapy (adriamycin or cisplatin) in the treatment of gastric cancers overexpressing bromodomain-containing protein 9 (BRD9). This evidence concerns the gene BRD9 and gastric cancer.